Ivan C N Fung

Ivan C N Fung

Auto-generated profile, based on publicly available information

Ivan C N Fung

Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
IFIvan C N Fung
Ivan C N Fung
PKPim J Koelink
Pim J Koelink
LMLieven G M Mulders
Lieven G M Mulders
IAIris Admiraal
Iris Admiraal
CVCaroline Verseijden
Caroline Verseijden
WJWouter de Jonge
Wouter de Jonge
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing and remitting mucosal inflammation of the colon. While active UC mucosa is characterized by dysregulated B cell responses and increased B cell and IgG plasma cell populations, targeting CD20-expressing B cells in UC has proven ineffective. Methods: We conducted an exploratory single-cell transcriptomic analysis of colonic biopsies obtained from UC patients with (n = 5) or without (n = 5) active inflammation, and non-UC controls (n = 4). To explore whether B cells contribute to colitis severity, we transferred various ratios of spleen-derived naive B cells with CD45RBhigh T cells into severe combined immune deficient mice to induce colitis. Results: Our analysis identified a distinct subset of naive (MS4A1+CD27-IGHD+TCL1A+) B cells that are significantly enriched and present a more matured phenotype in inflamed compared to non-inflamed biopsies from UC patients. Cell-cell communication analysis indicated that naive B cells interacted predominantly with CD4+ T cell subsets. In the mice transfer colitis model, co-transfer of naive B cells at a ratio of 1-2 T and B cells, respectively, showed an increased maturation and activity, which led to exacerbation of colitis as measured by weight loss, increased colon density, and histological inflammation. Conclusion: Our findings suggest that naive B cells expand in actively inflamed mucosa from UC patients and play a pathogenic role in experimental colitis.

8 May 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
LWLina Wehkamp
Lina Wehkamp
DHDanielle M M Harris
Danielle M M Harris
NKNa-Mi Kim
Na-Mi Kim
AAAbrar I Alsaadi
Abrar I Alsaadi
QWQicong Wu
Qicong Wu
KAKonrad Aden
Konrad Aden
Background: Inflammatory bowel disease (IBD) is associated with energy deficiency and perturbed metabolism of the essential amino acid tryptophan (Trp). Objective: We aimed to determine whether excessive Trp degradation fuels or compensates for inflammation through de novo nicotinamide adenine dinucleotide (NAD+) synthesis. Design: A prospective systems medicine approach (metabolomics, transcriptomics) was employed longitudinally in patients with advanced IBD therapy. Findings were validated with targeted Trp metabolomics in experimental colitis and in vitro in fibroblasts, intestinal epithelial cells (IECs), and peripheral blood mononuclear cells (PBMCs). Results: Active IBD is marked by enhanced Trp degradation driven by inflammatory cytokines through the JAK/STAT pathway. Trp catabolism results in accumulation of quinolinic acid (QA) and NAD + depletion due to reduced expression of QPRT, the enzyme converting QA to NAD+. QPRT knockdown enhances inflammation, while NAD + precursor supplementation (e.g. nicotinamide riboside [NR]) restores cellular energy and reduces inflammation in vitro and in dextran sodium sulfate (DSS)-induced colitis. Conclusion: A metabolic bottleneck at QPRT prevents efficient NAD+ synthesis from Trp in IBD, sustaining inflammation. Restoring NAD + is a promising therapeutic strategy.

8 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
IFIvan C.N. Fung
Ivan C.N. Fung
DJDjuna C. de Jong
Djuna C. de Jong
KLKe Liu
Ke Liu
AYAndrew Li Yim
Andrew Li Yim
SGSara van Gennep
Sara van Gennep
GDGeert R. D’HAens
Geert R. D’HAens
B ackground & O bjective: Tofacitinib, a Janus kinase (JAK) inhibitor, is approved for ulcerative colitis (UC). We investigated baseline and longitudinal transcriptomics and proteomics in intestinal biopsies, peripheral blood, and serum from UC patients starting tofacitinib to characterize treatment-associated effects and identify which molecular compartment harbors the most predictive response-associated biomarkers. M ethods: In this prospective, open-label study, patients with moderately to severely active UC started tofacitinib 10 mg BID for eight weeks. Clinical, biochemical, endoscopic, and histological data were collected at baseline and week 8. The primary outcome, histo-endoscopic mucosal improvement (HEMI), was defined as endoscopic Mayo subscore ≤1 with histologic remission (Robarts Histopathology Index ≤3, no mucosal neutrophils). Mucosal biopsies and peripheral blood were collected at baseline and week 8 for bulk RNA-sequencing (RNA-seq); biopsies and serum underwent proteomic profiling using Olink Explore 384 (Cardiometabolic, Inflammation, Neurology, Oncology panels). R esults: In total, 127 paired multi-omic samples were collected longitudinally from 40 UC patients: 15 (38%) achieved HEMI at week 8 (responders), 13 (32.5%) were late responders, and 12 (30%) were non-responders. Pretreatment mucosal biopsies from future responders showed elevated interferon, IL-6-family, IL-2/common-γ-chain, and T-cell-receptor signaling gene expression, which declined on treatment only in responders. A responder-specific JAK-STAT-dependent mechanism spanned interferon, cytokine-receptor, T-cell-receptor, and NF-κB signaling, with concordant gene- and protein-level reductions. Compared with a public infliximab dataset, JAK-STAT/interferon downregulation was shared and response-independent, while non-canonical NF-κB downregulation was tofacitinib-specific. In blood, shared pathway labels reflected distinct genes from mucosal effectors. C onclusion: Response to tofacitinib depends on a JAK-tractable mucosal pathway absent in non-responders, suggesting a pretreatment biomarker for predicting treatment response. What is already known on this topic: Prior studies have individually interrogated transcriptomic and/or epigenomic signatures of tofacitinib response as a single modality. What this study adds: Our study provides simultaneous profiling of both the transcriptome and proteome across paired mucosal and systemic compartments in patients, comparing responders with non-responders at baseline and over time. Our data support a model where tofacitinib response in UC depends on a JAK-dependent pro-inflammatory phenotype that the drug can dismantle, in contrast to non-responders representing distinct, JAK-independent pathways. How this study might affect research, practice or policy: This study provides a foundation for treatment response studies in UC towards the development and validation of predictive biomarkers in colonic mucosa and blood, which could ultimately result in more personalized treatment strategies.